title: Clinical and economic choices in the treatment of respiratory infections in cystic fibrosis: comparing hospital and home care.
abstract: BACKGROUND
  A cost-effectiveness evaluation comparing home-based and hospital-based treatment with intravenous antibiotics for respiratory exacerbations in adults with cystic fibrosis (CF) has not been previously undertaken.
  
  
  METHODS
  The study was conducted in a UK adult CF centre from a health service perspective. Clinical outcome and resource use data were obtained from a retrospective one-year study and combined with unit cost data in an incremental economic analysis. The primary outcome measure was percentage change in FEV(1); "effectiveness" was defined as maintenance of baseline average FEV(1) over the one-year study period.
  
  
  RESULTS
  116 patients received 454 courses of intravenous antibiotics. At the end of 1 year, there had been a mean percentage decline in FEV(1) compared with baseline average for home-treated patients but an improvement for hospital-treated patients (Tukey's HSD mean difference 10.1%, 95% CI 2.9 to 17.2, p = 0.003). Treatment was deemed "effective" in more hospital (58.8%) than home (42.6%) patients. The cost of hospital treatment was higher than home treatment (mean difference 9,005 pounds, 95% CI 3,507 to 14,700, p<0.001). The mean ICER was 46,098 pounds (2.5th and 97.5th percentiles -374,044 and 362,472).
  
  
  CONCLUSIONS
  Hospital treatment was more effective but more expensive than home treatment. Potential methods to improve outcome at home should be considered but these may have resource implications.
authors.affiliation: School of Pharmacy and Pharmaceutical Sciences, University of Manchester M13 9PL, UK. judith.thornton@manchester.ac.uk
authors.forename: J
authors.initials: J
authors.lastname: Thornton
authors.forename: R A
authors.initials: RA
authors.lastname: Elliott
authors.forename: M P
authors.initials: MP
authors.lastname: Tully
authors.forename: M
authors.initials: M
authors.lastname: Dodd
authors.forename: A K
authors.initials: AK
authors.lastname: Webb
mesh_terms: D000704:Analysis of Variance; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D003362:Cost-Benefit Analysis; D003550:Cystic Fibrosis / Q000382:microbiology*; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006699:Home Care Services / Q000191:economics*; D006782:Hospitals, Special / Q000191:economics*; D006801:Humans; D007262:Infusions, Intravenous; D008171:Lung Diseases / Q000188:drug therapy* / Q000382:microbiology; D008297:Male; D012189:Retrospective Studies; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D000900:Anti-Bacterial Agents